CaroGen announces the publication of Its CARG-2020 preclinical data on Ovarian Cancer in the Journal of Cancer Immunology Research
Farmington, CT, December 14, 2023– CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology clinical candidate for ovarian cancer, has been published in the Journal of Cancer Immunology Research (Alvero et al. Cancer Immunol Res (Dec. 2023, in press)).
CaroGen Announces the Publication of Its Cancer Immunotherapy CARG-2020 Preclinical Data
Farmington, CT, September 20, 2023 – CaroGen Corporation, a developer of transformative immunotherapies for cancer and infectious diseases, announced today that preclinical data on CARG-2020, its flagship immuno-oncology candidate for solid tumors, has been published in the Journal of Acta Pharmaceutica Sinica B (https://doi.org/10.1016/j.apsb.2023.08.034).
Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory.
Ayesha B. Alvero, Alexandra Fox, Bhaskara Madina, Marie Krady, Radhika Gogoi, Hussein Chehade,Valerian Nakaar, Bijan Almassian, Timur Yarovinsky, Thomas Rutherford and Gil Mor.
Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence.
Ju Chena, Bhaskara Reddy Madina, Elham Ahmadi, Timur Olegovich Yarovinsky, Marie Marthe Krady, Eileen Victoria Meehan, Isabella China Wang, Xiaoyang Ye, Elise Pitmon, Xian-Yong Ma, Bijan Almassian, Valerian Nakaar, Kepeng Wanga
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models
Ayesha Alvero, MD, MSc, professor, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Novel Immunomodulatory virus CARG-2020 for Recurrent ovarian cancer
At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer in Tampa, Florida, Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan, discusses the use of the novel immunomodulatory virus CARG-2020 to restore immunosurveillance and establish anti-tumoral immunological memory to prevent ovarian cancer recurrence.
CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy to be Presented Orally at the Society of Gynecologic Oncology Annual Meeting
Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that new preclinical data about the mechanism of action of CaroGen’s novel ovarian cancer immunotherapy, CARG-2020,
CaroGen Management to Speak at The World Vaccine & Immunotherapy Congress
Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com), a developer of transformative immunotherapies for cancer and infectious diseases, today announced that Bijan Almassian, PhD, President & CEO,
Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine – BioCT | 21 comments
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine.
“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide chronically infected with hepatitis B virus (HBV). Currently there is no cure for HBV.
CaroGen and Wayne State University scientists report significant progress on development of CARG-2020 for the potential treatment of ovarian cancer
Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University..
UConn Health, CaroGen Collaborate on Promising Technology for Colorectal Cancer Treatment
UConn Health researchers, along with industry partners, have developed a promising potential candidate for treating colorectal cancer.
